药物输送联合研究与许可协议（2019-2024）

Drug Delivery Collaboration and Licensing Deals 2019-2024

出版日期: 2024年11月01日 | 出版商:

Current Partnering | 英文 750+ Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

该报告审查了药物输送合作和许可协议，以详细瞭解和分析了公司如何以及为何签订药物输送协议。

介绍
过去几年的药品传输合约
最活跃的药物传输合约公司
药物输送：依合约类型
药物传输：按治疗领域
药物输送：依行业分类
药物输送协议的条款与条件
- 药品配送合约总金额
- 药物输送合约的预付款
- 药物输送合约的里程碑付款
- 药物输送特许权使用费率

第3章重大药品输送合约

介绍
按价值排名最高的药物输送合约

第4章：最活跃的药品输送合约公司

介绍
最活跃的药物传输合约公司
最活跃的药物传输合约公司概况

第5章药品交付合约名录

介绍
药品输送合约目录

第6章药品输送合约：依技术类型

合约目录
合约目录 - 药物输送合约：按公司（AZ）
合约目录 - 药品输送合约：依合约类型
合约目录 - 药物传输合约：依治疗领域
定义合约类型
关于Biopharma Research Ltd
目前的合作伙伴
目前协议
目前合作伙伴最近报告的标题

简介目录

Product Code: CP2102

Drug Delivery Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the drug delivery deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of drug delivery deals from 2019 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1202 drug delivery deals announced since 2019 including financial terms where available including links to online deal records of actual drug delivery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of drug delivery dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in drug delivery dealmaking since 2019.

Chapter 3 provides an overview of the leading drug delivery deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in drug delivery dealmaking with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of drug delivery deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since Jan 2019. The chapter is organized by specific drug delivery technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in drug delivery deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Drug Delivery Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse drug delivery collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Drug Delivery Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of drug delivery trends and structure of deals entered into by leading biopharma companies worldwide.

Drug Delivery Collaboration and Licensing Deals includes:

Trends in drug delivery dealmaking in the biopharma industry
Directory of drug delivery deal records covering pharmaceutical and biotechnology
The leading drug delivery deals by value
Most active drug delivery licensing dealmakers
Drug Delivery Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in drug delivery dealmaking

2.1. Introduction
2.2. Drug delivery deals over the years
2.3. Most active drug delivery dealmakers
2.4. Drug delivery deals by deal type
2.5. Drug delivery deals by therapy area
2.6. Drug delivery deals by industry sector
2.7. Deal terms for drug delivery deals
- 2.7.1 Drug delivery deals headline values
- 2.7.2 Drug delivery deal upfront payments
- 2.7.3 Drug delivery deal milestone payments
- 2.7.4 Drug delivery royalty rates